SCHEMBL7089898

SCHEMBL7089898

COc1ccc2c(C=O)cccc2c1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B10 O60218 1/20 0.47
AKR1A1 P14550 1/20 0.47
AKR1B1 P15121 1/20 0.47
ERN1 O75460 8/20 0.45
TLR2 O60603 1/20 0.45
TLR1 Q15399 1/20 0.45
TLR6 Q9Y2C9 1/20 0.45
SRC P12931 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MCL1 Q07820 1/20 0.38
NFE2L2 Q16236 1/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18124631 0.82 ERN1 (0.56) ERN1TLR2TLR1TLR6SRC
SCHEMBL15565633 0.78 ENPP2 (0.44) AKR1B10AKR1A1AKR1B1
SCHEMBL15565631 0.78 ENPP2 (0.44) AKR1B10AKR1A1AKR1B1
SCHEMBL28289589 0.78 ERN1 (0.50) ERN1TLR2TLR1TLR6SRC
SCHEMBL9489666 0.78 AKR1B10 (0.48) AKR1B10AKR1A1AKR1B1ALDH1A1CYP1A2
SCHEMBL31362059 0.77 ERN1 (0.61) ERN1TLR2TLR1TLR6SRC
SCHEMBL2988767 0.77 ERN1 (0.61) ERN1TLR2TLR1TLR6SRC
SCHEMBL10943367 0.76 PIM1 (0.38) ERN1ALDH1A1LMNACYP1A2KDM4E
SCHEMBL10677181 0.76 IDO1 (0.53) AKR1B10AKR1A1AKR1B1MCL1ALDH1A1
SCHEMBL9575279 0.76 IMPDH2 (0.57) AKR1B10AKR1A1AKR1B1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4408077-A 6-(Lower alkoxy)-5-(trifluoromethyl)-1-naphthalenecarboxaldehydes AYERST, MCKEENA & HARRISON, INC. (CA) 1983-10-04 US claimed
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 AKR1B10 28/4885AKR1A1 5/4885AKR1B1 6/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 AKR1B10 8/4885AKR1A1 2/4885AKR1B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.